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On Sharing Quantitative Trait GWAS Results
in an Era of Multiple-omics Data and the Limits
of Genomic Privacy
Hae Kyung Im,1,* Eric R. Gamazon,2 Dan L. Nicolae,2,3,4 and Nancy J. Cox2,3,*
Recent advances in genome-scale, system-level measurements of quantitative phenotypes (transcriptome, metabolome, and proteome)
promise to yield unprecedented biological insights. In this environment, broad dissemination of results from genome-wide association
studies (GWASs) or deep-sequencing efforts is highly desirable. However, summary results from case-control studies (allele frequencies)
have been withdrawn from public access because it has been shown that they can be used for inferring participation in a study if the
individual’s genotype is available. A natural question that follows is how much private information is contained in summary results
from quantitative trait GWAS such as regression coefficients or p values. We show that regression coefficients for many SNPs can reveal
the person’s participation and for participants his or her phenotype with high accuracy. Our power calculations show that regression
coefficients contain as much information on individuals as allele frequencies do, if the person’s phenotype is rather extreme or if
multiple phenotypes are available as has been increasingly facilitated by the use of multiple-omics data sets. These findings emphasize
the need to devise a mechanism that allows data sharing that will facilitate scientific progress without sacrificing privacy protection.Introduction
Homer et al.1 showed that it is possible to detect an individ-
ual’s presence in a complex genomic DNA mixture even
when the mixture contains only trace quantities of his or
her DNA. The study considered the implications of its find-
ings, motivated originally as an application to forensic
science, in the context of genome-wide association studies
(GWASs) fromwhich aggregate allele frequencies for a large
number of markers were being made publicly available.
Shortly after this publication, a reduction in open access
to aggregate GWAS results was implemented. Jacobs et al.2
presented an improved method using a likelihood
approach and showed that disease status could be inferred
for participants of the study. Visscher et al.3 and Sankarara-
man et al.4 calculated power estimates to understand the
limits of individual detection from sample allele frequen-
cies. They showed that the power to detect membership is
determined by the ratio between the number of markers
and the number of participants in the study.
Wepresent amethod that can infer an individual’s partic-
ipation in a study when regression coefficients from
quantitative phenotypes are available. This problem is
especially relevant now that genome-wide system-level
measurements of quantitative phenotypes (transcriptome,
proteome, and metabolome) are being widely collected
and analyzed. Undoubtedly, disseminating results from
quantitative GWAS and deep-sequencing efforts could be
of enormous benefit to research groups working on related
traits. We explore several statistics that can discriminate
study participants from nonparticipants. Notably, we find
that the use of only the direction of effects (signs of the1Department of Health Studies, University of Chicago, Chicago, IL, 60637, USA
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The Amcoefficients) enables membership inference with good
accuracy. We show the results from applying the statistics
to the Genetics of Kidneys in Diabetes (GoKinD) data
set5,6 to illustrate the level of information contained in
aggregate data. We also provide quantification of the infor-
mation content by computing the power of the method.
Furthermore, we discuss a general framework that can be
used for integrating our findings and earlier studies of
genomic privacy based on sample allele frequencies. With
the increasing use of high-throughput technologies to inte-
gratemultiple-omics data sets, these various statistics result
in a more powerful approach to the identification problem
than with the use of a single phenotype.Material and Methods
Let us assume that we have the estimated regression coefficients
for M independent SNPs, that we use data on n individuals in a
GWAS (test sample), and that we also have the allelic dosage for
n individuals from a reference population such as HapMap7,8 or
1000 Genomes Project.9Membership Inference Method
We define a statistic (a function of available data) that has a
different distribution depending on the membership status and
use this difference to infer membership. We compute this statistic
for the individual of interest, I, and for all individuals in the refer-
ence population. If the statistic falls well within the reference
distribution we will conclude that the individual is not likely to
have participated in the study, and if the statistic falls in the
extremes of the distribution, we will conclude that the individual
did participate in the study.; 2Department of Medicine, University of Chicago, Chicago, IL, 60637, USA;
0637, USA; 4Department of Statistics, University of Chicago, Chicago,
.)
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Let bY be defined as
bYI ¼ n
M
XM
j¼1
bbjXI;j  bXj; (Equation 1)
where XI;j is the allelic dosage of individual I at SNP j, bbj is the
estimated coefficient from fitting the model Yi ¼ aj þ bjXi;j þ ei,
and bXj is the estimated mean of allelic dosage (twice the allele
frequency) for SNP j computed with the reference group.
Conditional Mean and Variance of bY
The expected value and the variance of the statistic bYI conditional
on the individual’s genotype XI and demeaned phenotype YI  m
and membership status (in or out) are as follows:
E½bY jXI ;YI ; inzðYI  mÞ
E½bY jXI ;YI ; outz0
Var½bY jXI ;YI ; inzs2 n
M
Var½bY jXI ;YI ; outzs2 n
M
; (Equation 2)
where s2 is the variance of the phenotype, and m is the population
mean of the phenotype Y. Note that for the method to work we do
not need to make use of these expressions nor do we need to know
s2 and m because we rely on the empirical distribution from the
reference population to determine membership. These expres-
sions will serve to estimate the power of the method.
Unconditional on YI, the variance of the statistic bY is given by
Var
bY jXI ; inzs2:
In computing these quantities we assume that the number of
markers is much larger than the number of individuals in the
test sample and the number of individuals in the reference group:
M >> n >> 1 andM >> n >> 1. Hardy Weinberg equilibrium is
assumed. To derive these expressions, we used standard Taylor
expansions and the law of iterative expectations. We tested the
validity of these for finite samples (n between 100 and 1,000 and
M=n between 1,000 and 50,000) by fitting linear regressions
with simulated genotypes and phenotypes and computing the
sample mean and variances of the bY statistic. See Supplemental
Data, available online, to find plots of the validation.
Power of the Method
To compute power, we define the null and alternative hypothesis.
Under the null hypothesis the individual did not participate
in the study (nor did any relatives of the individual), whereas under
the alternativehypothesis, the individual didparticipate.Using the
mean and variance under the null hypothesis and the correspond-
ingmean and variance under the alternative hypothesis computed
in Equation 2 and assuming M >> n >> 1; M >> n >> 1,
normality of the statistic bY , and the sign of YI  m to be known,
the power will be approximately given by
powerzF
 
jYI  m j
s
ﬃﬃﬃﬃﬃ
M
n
r
 za
!
; (Equation 3)
where a is the type I error, zx ¼ F1ð1 xÞ is the ð1 xÞ-quantile of
the normal distribution, and F is the normal cumulative distribu-
tion function. If the sign of bY  m is not known, a two-sided test
will be used in the derivation and the power will be given by
powerzF
 
jYI  m j
s
ﬃﬃﬃﬃﬃ
M
n
r
 za=2
!
: (Equation 4)592 The American Journal of Human Genetics 90, 591–598, April 6, 2See derivation in Appendix A. Because F is a strictly increasing
function the power
d increases when M, the number of SNPs, increases
d decreases when n, the study’s sample size, increases
d increases when the individual’s phenotype deviates more
from the mean (scaled by the standard deviation)
d increases when a, the type I error, increases
To facilitate comparison with Visscher et al.3 and Sankararaman
et al.,4 let us express the one-sided power Equation 3 with the
following (equivalent) implicit formula
ðza þ zbÞ2z

YI  m
s
2
M
n
; (Equation 5)
where 1 b is the power (note that in Sankararaman et al.4 b is
defined as the power). Recall that in Visscher et al.3 and Sankarara-
man et al.4 power was given implicitly by
ðza þ zbÞ2zM
n
: (Equation 6)
Thus, the only difference between Equations 5 and 6 is the factor
ððYI  mÞ=sÞ2. If the phenotype of the person deviates more than
one standard deviation away from the mean, i.e., jYI  mj > s
and the sign of YI  m is known, the power when regression
coefficients are used is larger than it is when allele frequencies
are used. If the person’s phenotype is close to the mean, then
the power will be much diminished. Although expectations are
computed conditional on YI  m, we do not need to know its
magnitude in order to achieve this power. However, we do need
to know the sign of YI  m in order to keep the test one-sided.
If the sign is not used, jYI  mj would need to be 1þ
ðza=2
zaÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
M=n
p 
times greater than the standard deviation in order
to achieve greater power than the allele frequency case. As an
example, if a ¼ 0:05 and M=n ¼ 100, jYI  mj would need to be
greater than 1.031 times s.Individual Contribution to the Regression Coefficient
In order to get an intuitive understanding of the contribution
of each individual from the sample, we can decompose the esti-
mated regression coefficient into roughly the sum of individual
contributions:
bbj ¼  ~X0j ~Xj1 ~X0j ~Y
bbjz 1ns2j ~XI;j ~YI þ 1ns2j
X
isI
~Xi;j ~Yi
bbjz ~bI;j þP
isI
~bi;j
; (Equation 7)
defining ~bi;j ¼ ð1=ns2j Þ ~Xi;j ~Yi as the individual contribution to the
regression coefficient and s2j as the variance of the allelic dosage
(under Hardy Weinberg assumption s2j ¼ 2pjð1 pjÞ where pj is
the minor allele frequency of SNP j). We use the tilde ~X for the
demeaned variable that uses themean from the sample. It is worth
comparing with the decomposition for the case whenminor allele
frequencies for the sample are available: bpjzðpI;j=nÞ þPisI ðpi;j=nÞ,
where bpj is the sample minor allele frequency and pi;j is the allelic
dosage divided by 2 of individual i for SNP j. This similarity gives
an intuitive understanding of the corresponding similarity in the
dependence of power on the ratio of the number of SNPs and
sample size of the study.012
Combining Multiple Phenotypes
If results from multiple phenotypes such as eQTL (or other omics
data) results are available, we can combine the information
regarding the individual’s membership by using a Fisher type of
method (the sum of logarithms of p values).10
For each phenotype k, we can compute an empirical p value, pk,
defined as the proportion of reference individuals with magnitude
of the jbY j greater than the individual’s jbYI j. We can combine
p values across different phenotypes by computing
2
Xnpheno
k¼1
log10 pk
where npheno is the number of phenotypes to be combined. In
addition to accumulating evidence across phenotypes, this
method avoids the problem of lack of power due to one particular
phenotype being close to the population mean.
Covariate Adjustment
Usually other covariates such as age, sex, etc. are adjusted for
when performing GWASs. If the allelic dosage is independent of
the covariates (as will likely be the case for most SNPs) bY will
converge to the covariate-adjusted phenotype instead of the actual
phenotype. The standard deviation might change if the covariates
explain a substantial portion of the phenotypic variability.
However, the method will still work because under no participa-
tion bY will still be around 0, whereas if the individual participated
in the study, bY will converge to the covariate-adjusted phenotype.
Themethod does not require knowing the actual phenotype and it
will work relative to this adjusted phenotype. For the purpose of
re-identification using our method, the presence of covariates is
only a nuisance and no additional power is achieved when they
are present.
Sample Correlation Statistic
Equation 7 suggests that the sample correlation between the esti-
mated beta and the individual’s genotype might be useful because
we would expect the correlation to be 0 if the individual was not in
the sample and different from 0 if the individual was part of the
study.
bC ¼
PM
j¼1
bbj  bXI;j  bXj XI  bXﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
j
bbj  b2P
j

XI;j  bXj XI  bX2s ;
where the long bar above an expressionmeans the samplemean of
the expression.
Sign Statistic
Equation 7 also shows that the sign of the correlation coefficient
will be slightly more likely to match the sign of the demeaned
allelic dosage if the person participated in the study than other-
wise. Let bS be defined as:
bS ¼XM
j¼1
sign
bb signXi;j  bXj
We expect that strictly more than 50% of the times the product
signðbbÞ signðXi;j  bXjÞ will be positive (or negative) if the indi-
vidual participated in the study and his or her phenotype is above
(or below) average. By looking at the absolute value of the signThe Amstatistic we expect to gain information on whether the individual
was part of the study or not.
Analysis Details
We used the PLINK software11 and filtered out SNP markers that
were not in Hardy Weinberg equilibrium (p < 0.001) and those
that had minor allele frequencies less than 5%. Receiver operating
characteristic (ROC) curves were generated by using the absolute
value of the statistic as the predicting variable and membership
in the sample as the labels by using the ROCR12 package for the
R statistical package.13 We used only individuals who self-reported
as white both for sample and reference.Results
We show the performance of the statistics defined inMate-
rial and Methods ðbY ; bS; bCÞ by using data from the GoKinD
(Genetics of Kidney Disease) study.5,6 The data set was
downloaded from dbGaP14 and consisted of more than
1,800 probands with long-standing type 1 diabetes, over
300 dichotomous and quantitative phenotypes, and geno-
type from Affymetrix Genome-Wide Human SNPArray 5.0
platform.We used a subset of 1,644 individuals reported to
be Caucasian.
We show results for two of the phenotypes: cholesterol
level and body mass index (BMI). We also tested the
method on a third simulated phenotype and found at least
as good performance. The latter demonstrates that the
method does not depend on any real effect of genotype
on phenotype.
We randomly sampled 100, 500, and 1,000 individuals
from each study’s cohort and performed a GWAS including
only individuals from each random sample. The remaining
individuals were used as reference group. The statistics
ðbY ; bS; bCÞ were computed for both sample and reference
individuals.
Identifiability Statistic and Phenotype Reconstruction
Figure 1 shows bY versus the actual phenotype (rank
normalized cholesterol levels). The blue dots correspond
to individuals in the sample and the black dots correspond
to individuals in the reference group. For individuals in the
sample, bY lies close to the one-to-one line (perfect predic-
tion line), whereas the individuals in the reference popula-
tion lie close to a flat line around 0 (consistent with our
calculations of mean and variances). The sample size was
n ¼ 1; 000 and the number of SNPs was M ¼ 300;000.
The number of reference individuals was 644.
This demonstrates that for individuals who participated
in a study, their phenotype can be reconstructed with high
accuracy using the bY statistic, whereas for nonparticipants
what we get is mostly noise.
Distribution of Statistic by Membership Status
and ROC Analysis
The left panel in Figure 2 shows the distribution of the
absolute value of bY by membership status. As in Figure 1
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Figure 1. bY versus YbY versus the actual phenotype (cholesterol levels with normal-
izing transformation applied). The blue dots correspond to indi-
viduals in the sample and the black dots correspond to individuals
in the reference group. For individuals in the sample bY lies close to
the one-to-one line, whereas the individuals in the reference pop-
ulation lie close to a flat line around 0. The sample size was 1,000
and number of SNPs was 300,000.
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Figure 2. bY Distribution by Membership Status and
Performance
(Left panel) The distribution of the absolute value of bY by
membership status. As in Figure 1 nonmembers’ values lie close
to 0, whereas the values for participants are distributed similar to
the actual phenotype.
(Right panel) The ROC curve, the true positive rate (sensitivity)
versus the false positive rate (1-specificity) when we use jbY j
to predict membership. A good test should yield a high true posi-
tive rate (sensitivity) while keeping the false positive rate low
(1-specificity); ideally the AUC should be close to 1. For 300,000
SNPs and a sample size of 1,000, the AUC was 0.83, which is
reasonably close to 1.nonmembers’ values lie close to 0, whereas members’
values are distributed in a large range of values. This differ-
ence in distributions is what will allow us to discriminate
between members and nonmembers.
The right panel shows the ROC curve, the true positive
rate (sensitivity or power) versus the false positive rate
(1-specificity or type I error) when we use jbY j to predict
membership. A good test should yield a high true positive
rate (¼ sensitivity or power) while keeping the false posi-
tive rate low (¼ 1-specificity or type I error); ideally the
area under the curve (AUC) should be close to 1. For
300,000 SNPs and a sample size of 1,000, the AUC was
0.83, which is much greater than 0.5, showing clear
discrimination power. The poor performance relative to
the allele frequency case is due to the fact that we do not
assume the sign of the deviation from the mean to be
known and that the phenotype values of some of the indi-
viduals in the test sample are close to the mean. Recall
from Equation 3 that power (which is not equal to AUC
but is a related measure of performance) is an increasing
function of the absolute value of the difference between
the phenotype and the mean. For average individuals
(phenotype close to the mean) this method does not
provide discrimination power.
Predictive Performance as Function of M/n
Figure 3 shows the area under the curve for different values
of sample size (n) and number of SNPs (M). Consistent with
our power calculation, we observe increasing performance
as the ratio of number of SNPs to sample size increases.594 The American Journal of Human Genetics 90, 591–598, April 6, 2SNPs were chosen randomly from the full set of available
SNPs. The lower AUC for larger sample sizes is probably
because the independence of markers assumption fails
more dramatically as the total number of markers
increases.
Performance of Other Statistics and Their Information
Content
Figure 4 shows the distribution and performance of the
sign statistic. The left panel shows the distribution of the
sign statistic by membership status. The right panel shows
the ROC curve when we use the absolute value of the sign
statistic to predict membership. Notice that the area under
the curve is 0.75, which still shows good discrimination
power. This result suggests that a large portion of the
information regarding the individual’s participation is
contained in the signs.
The performance of the correlation statistic is almost
identical to the performance of bY as one might have ex-
pected.
Covariate Adjustments
Figure 5 shows the ROC curve for bY with rank normalized
cholesterol levels as phenotype and sex and age as
covariates in addition to allelic dosage. Note that the
performance has not changed by adding the additional
covariates. This was expected because our method is based
on ‘‘over fitting’’ of the data.
In general access to the covariates or phenotypes for the
participants is not available and so we did not attempt to
improve our method by using them. If the allelic dosage
is independent of the covariates (as will likely be the case
for most SNPs), bY will converge to the covariate-adjusted
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Figure 3. Performance by Sample Size and Number of Markers
The plot shows the area under the curve for different values of
sample size (n) and number of SNPs (M). Consistent with the
power calculation, we observe increasing AUC as the ratio of
number of SNPs to sample size increases. The lower AUC for
sample sizes of 1,000 is probably due to a more pronounced effect
of linkage disequilibrium as we use more markers.
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Figure 4. Sign Statistic Distribution and Performance
The left panel shows the distribution of the sign statistic by
membership status. The right panel shows the ROC curve when
we use the absolute value of the sign statistic to predict member-
ship. The area under the curve is 0.75, a bit lower than the AUC
when the actual estimated coefficients are used, but it still shows
good discrimination. This suggests that a large portion of the
information regarding individual’s membership is contained
in the signs rather than in the absolute value of the regression
coefficient.phenotype, and our method will work relative to this
adjusted phenotype. We do not expect the inclusion of
covariates to affect the performance of the method. Also
note that our method relies on ‘‘over fitting’’ of the data
that occurs for individuals in the sample and not on any
real relationship between genotype and phenotype. As
previously mentioned, we found that the method worked
equally well when a simulated phenotype was used.
Multiple Phenotypes
To illustrate the effect of combiningmore than one pheno-
type, we applied the Fisher type method (the sum of the
log of empirical p values, see details in Methods) to choles-
terol and Body Mass Index (BMI) regression coefficients.
Figure 6 shows the ROC curves when single phenotypes
were used compared to the curve when both were com-
bined. Clearly, the combined method outperforms both
single-phenotype methods. The AUC for each phenotype
was 83% and 87%, whereas the combined AUC is 95%.
The performance should improve as the number of pheno-
types increases.Discussion
Given the increasing number of large-scale data sets in
which very large numbers of phenotypes will be subject
to GWAS or sequencing studies, it is of great interest toThe Amquantify the level of participant’s private data contained
in aggregate results. The insights gained from our study
should be helpful in devising methods to facilitate broad
dissemination of study results without compromising the
participant’s privacy.
We present three statistics that can discriminate between
individuals who participated in a study and those who did
not. We show the performance of themethod by using real
data from the GoKind GWAS. We also provide an approx-
imate estimate of the power of the method when bY (the
average of the regression coefficients times the allelic
dosage) is used. Power is determined by the ratio between
the number of markers and the sample size of the study,
much like when allele frequencies are available. But the
power is also modulated by the deviation from the mean
of the individual’s phenotype. This indicates that for indi-
viduals with extreme phenotypes (e.g., as expected from
certain study designs), more power can be achieved
(asymptotically) through the use of the regression coeffi-
cients than through the use of allele frequencies. But for
a person with an average phenotype the method provides
no power, which is expected because the average person
contributes very little to the estimate of the regression
coefficients. In an earlier study, Lumley and Rice15 consid-
ered the possibility that aggregate results from GWAS can
reveal a participant’s phenotype with high accuracy, even
for quantitative phenotypes. However, the problem of
phenotype reconstruction (the subject of Lumley et al.’s
Commentary on quantitative traits15) for a participant of
a study and the problem of identifiability are distinct prob-
lems; furthermore, the problem of identifiability was not
theoretically explored. Here we quantified the power of
our identification method for quantitative traits, demon-
strated the existence of various statistics that can detect
the presence of individual genotypes from summaryerican Journal of Human Genetics 90, 591–598, April 6, 2012 595
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Figure 5. Performance with Covariate Adjustment
This figure shows the ROC curve for bY with rank normalized
cholesterol levels as phenotype and sex, age, and allelic dosage
as covariates. Note that the performance is not changed by adding
the additional covariates. False positive rate
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Figure 6. Performance with Multiple Phenotypes
To illustrate the effect of combiningmore than one phenotype, we
applied the Fisher type method (the sum of the log p values) to
cholesterol and BMI regression coefficients. This figure shows
the ROC curves when each one of the phenotypes was used
compared to the curve when both were combined. Clearly, the
combined method outperforms both single-phenotype methods.
The AUC for each phenotype was 83% and 87%, whereas the
combined AUC is 95%.data, and sought to provide a general framework for
comparing the power with earlier studies3,4 of genomic
privacy based on sample allele frequencies.
The approximate decomposition of an individual contri-
bution to the regression coefficients gives us an intuitive
understanding of the level of information contained in
these aggregate data. This decomposition shows the struc-
tural similarity with the case in which allele frequencies are
used to infer membership.
Even though we do not claim that our method provides
optimal discrimination, the striking similarity between our
expression for power and the one obtained by Visscher
et al.3 and Sankararaman et al.4 leads us to believe that it
might not be far from optimal. In addition, the similarity
between an individual contribution to the regression coef-
ficients and the contribution to the sample allele
frequency adds credence to our hypothesis.
Tests on several other GWAS data sets yielded similar
results. As expected, we also found that the performance
depends on the homogeneity of the study participants.
Population structure would need to be taken into account
if the GWAS results included a heterogeneous cohort.
Although not presented here, we have seen that the bY
has a larger magnitude for relatives of study participants
than for the reference population. Thus, the method pre-
sented here should be applicable to determine whether
relatives of the individual participated in the study, albeit
with reduced power.
We have derived and applied our method to an additive
model but extension to other models (recessive, dominant,
etc.) should be straightforward.
It is interesting to note that by using only the signs of the
regression coefficients, we still maintain a large portion of
the discrimination power of the method. We have seen
similar effects in other data sets. One practical implication
of this finding is that reducing the number of decimals
in the published regression coefficients would not be an
effective method to protect privacy.596 The American Journal of Human Genetics 90, 591–598, April 6, 2If p values and signs were available, then regression
coefficients could be computed and our method would
identify participants. If only the p values are available,
the absolute values of the regression coefficients can be
calculated. The sign statistic suggests that we might be
able to guess the sign of the regression coefficient slightly
more often than 50% of the times. This would in principle
allow us to compute bY . However, the power is likely to be
substantially reduced.
It is worth noting that the ability to predict the pheno-
type using bY and to infer membership is not related to
any real effect of genotype on phenotype. We have seen
that the method works as well or better with simulated
phenotypes. We note that genotypic information is being
used to infer study membership and to reconstruct trait
value used in the estimates of regression coefficients; no
prediction of phenotypic status in new individuals is being
done.
Sensitivity and specificity give us information on the
probability of false positives or false negatives given the
individual participated in the study. In many cases, it
might be more relevant to look at false positive or negative
rates provided the individual was positive or negative ac-
cording to our testing method. These are represented by
positive or negative predictive values. The positive predic-
tive value can become very small if the prior probability
of the individual participating in the study is very low.
For example, if all we know about the individual is the
person’s gender, this probability could be as low as 105
or 106 (e.g., 1,000 participants out of 159 million male012
individuals from the USA). In this context, given that
the individual was positive in the test, the false negative
rate might still be very high. Naturally, because investiga-
tors have no control over how much prior information
someone can come up with, this argument cannot be
used to ignore the possible breach of confidentiality.
Results from massively parallel sequencing (in the
form of low frequency or rare genetic variations) might
enable increased power of identification. If results from
multiple phenotypes are available, as would be the case
if, for example, gene expression associations were also
conducted (and accompanying results made available),
the information from each phenotype can be combined
to achieve much greater power as suggested by the results
from combining just two phenotypes. Although the
single-phenotype method has no power for individuals
with an average phenotype, it is unlikely a person will
have an average phenotype for all the phenotypes
considered.
A recent study16 of temporal trends in the availability of
results from GWAS classified published studies according
to level of risk for potential misuse and highlights the
ongoing importance of clearer guidelines on how ‘‘data
products’’ can be appropriately shared.
With the increasing trend to collect and analyze
multiple-omics data, the need to share large amounts of
quantitative GWAS results becomes more urgent. In addi-
tion, given our finding that multiple phenotypes can be
combined to increase the power to infer membership, pro-
tecting privacy by limiting the number of significant hits
published is becoming less feasible.
Because fluid sharing of results among researchers for
legitimate scientific use would be highly desirable, our
study emphasizes the urgent need to devise protocols
and methods that facilitate this process without compro-
mising a participant’s privacy.
One mechanism to address this problem would be to
implement an annual certification process, which would
grant the certified researcher unrestricted access to study
results with the condition that the data could only be
used for research goals that do not compromise the partic-
ipants’ privacy. A researcher who does not abide by these
rules could be penalized by withdrawing further access
to data.Appendix A
Power Calculation
To compute power, we use the same assumptions as for the
conditional mean and variance, i.e., that the number of
markers is much larger than the number of individuals
in the test sample and the number of individuals in the
reference group: M >> n >> 1 andM >> n >> 1. Hardy
Weinberg equilibrium is assumed. Under these assump-
tions, it can be shown that bY converges to a normal variate
with mean and variance given in Equation 2.The AmWe define the null and alternative hypothesis as follows.
Under the null hypothesis, the individual did not partici-
pate in the study (nor did any relatives of the individual),
whereas under the alternative hypothesis, the individual
did participate.
If the method uses the sign of the difference YI  m,
and we assume that the difference is greater than 0, we
will reject the null hypothesis if bYI is greater than
zas
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n=M
p
, where a is the type I error and za is the ð1 aÞ
quantile of the normal distribution. The power will be
given by the probability under the alternative thatbYI > zas ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃn=Mp
power ¼ Pin
bYI > zas ﬃﬃﬃﬃﬃn
M
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(Equation 9)
¼ F
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s
ﬃﬃﬃﬃﬃ
M
n
r
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!
(Equation 10)
where in Equation (8) we have used the fact that bYI is nor-
mally distributed with mean YI  m and variance s2n=M
and in Equation (10) we have used the property of the
normal CDF FðxÞ ¼ 1 FðxÞ.
If YI  m < 0, similar arguments will give
power ¼ F
 
ðYI  mÞ
s
ﬃﬃﬃﬃﬃ
M
n
r
 za
!
:
Thus more generally we have
power ¼ F
 
jYI  m j
s
ﬃﬃﬃﬃﬃ
M
n
r
 za
!
: (Equation 11)
If the sign of the difference YI  m is not used, the rejec-
tion region will be defined as jbYI j > za=2s ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃn=Mp . The
alternative distribution will be an equally weighted
mixture of normal distributions with means jYI  mj and
jYI  mj. Note that any weight other than 1/2 would
mean that we have information on whether it is more
likely that the sign is positive or negative. For example, if
we knew it was more likely to be positive, then we would
give higher weight to the normal distribution with mean
jYI  mj. The power when we do not make use of the sign
of jYI  mj is given by
power ¼ Pin

j bYI j > za=2s ﬃﬃﬃﬃﬃn
M
r 
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bYI > za=2s ﬃﬃﬃﬃﬃn
M
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M
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Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/AJHG/.
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